Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 2Phase 1 1

Status

Completed 3

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Conditions

Leiomyoma 3Myofibroma 1Menorrhagia 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × ulipristal × Clear all
NCT00290251 2024-07-15

Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
72 enrolled 7 charts

Leiomyoma

NCT00044876 2019-12-17

Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
56 enrolled

Leiomyoma, Myofibroma

NCT02465814 2016-11-22

ASTEROID 2

Bayer

Phase 2 Completed
120 enrolled

Leiomyoma, Menorrhagia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡